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ABSTRACT
Allergen-specific immunotherapy (SIT) is the only available curative treatment of allergic diseases. Recent evi-
dence provided a plausible explanation to its multiple mechanisms inducing both rapid desensitization and
long-term allergen-specific immune tolerance, and suppression of allergic inflammation in the affected tissues.
During SIT, peripheral tolerance is induced by the generation of allergen-specific regulatory T cells, which sup-
press proliferative and cytokine responses against the allergen of interest. Regulatory T cells are characterized
by IL-10 and TGF-beta secretion and expression of important cell surface suppressive molecules such as cyto-
toxic T lymphocyte antigen-4 and programmed death-1 that directly or indirectly influence effector cells of aller-
gic inflammation, such as mast cells, basophils and eosinophils. Regulatory T cells and particularly IL-10 also
have an influence on B cells, suppressing IgE production and inducing the production of blocking type IgG4 an-
tibodies. In addition, development of allergen-specific B regulatory cells that produce IL-10 and develop into
IgG4 producing plasma cells represent essential players in peripheral tolerance. These findings together with
the new biotechnological approaches create a platform for development of the advanced vaccines. Moreover,
reliable biomarkers could be selected and validated with the intention to select the patients who will benefit
most from this immune-modifying treatment. Thus, allergen-SIT could provide a complete cure for a larger
number of allergic patients and novel preventive approaches need to be elaborated.
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INTRODUCTION
Immune tolerance is the “Holy Grail” of many fields
in which dysregulation of the immune system plays a
central role including allergy, asthma, autoimmunity,
organ transplantation and infertility. It is the prime
target for prevention and treatment strategies of
these disorders. Immune tolerance to allergens is
characterized by establishment of a long-term clinical
tolerance.1-4 It is now becoming clear that allergic dis-
eases are complex disorders and that there are sev-
eral disease variants caused by distinctive cellular
and molecular mechanisms. Although there are sev-
eral clinically relevant phenotypes for allergic rhinitis,
asthma, atopic dermatitis, chronic rhinosinusitis and
urticaria, these phenotypes do not provide any in-
sights into the mechanisms that underpin the dis-
eases.5,6 It is now thought that some clinical trials
may have previously been unsuccessful because they
were performed without attempting to classify pa-
tients into sub-groups defined by distinct pathophysi-
ologies, namely ‘endotypes’.5-7 It is generally ac-
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Table　1　What is unknown in the mechanisms of allergen-SIT
∙ Molecular mechanisms of how Treg cells are generated in vivo
∙ Better adjuvants that specifi cally induce Treg cells
∙ In vivo life span of Treg cells induced by allergen-SIT
∙ If there are deleterious roles of Treg cells, such as immune 
tolerance to tumor antigens and chronic infectious agents?
∙ Role of resident tissue cells in immune tolerance
∙ Molecular mechanisms of spontaneous healing, remissions 
and exacerbations of allergic disease
∙ Local tissue events during SLIT and epicutaneous SIT
∙ Early molecular markers and predictors to decide to start, 
stop and success
∙ Is there differences in the mechanisms of high dose and low 
dose allergen-SIT?
∙ Mechanisms of long term maintenance of allergen tolerance
∙ Is there any role in defective barrier function in the successful 
response to allergen-SIT?
cepted that there is an endotypephenotype of these
diseases that responds best to allergen-SIT,8 however
there are no appropriate biomarkers for patient selec-
tion. The best suitable models to study the mecha-
nisms underlying immune tolerance include the de-
velopment of a healthy immune response during high
dose of allergen exposure in beekeepers and cat own-
ers as well as the development of tolerance to aller-
gens induced by allergen-SIT.9,10 The described
mechanisms include changes in the profile of
allergen-specific memory T and B cell responses, the
synthesis of specific antibody isotypes that skew the
immune response towards a non inflammatory pat-
tern, as well as decreased activation, tissue migration
and degranulation of effector cells including mast
cells, basophils and eosinophils. The role of miRNAs
in the immune system is being studied since the dis-
covery of miRNAs in mammalian cells, and may rep-
resent biomarkers for SIT, because recent studies
clearly demonstrate the presence of extracellular
miRNAs in body fluids and propose the involvement
of miRNAs in cell-cell communication.11 In addition,
defects in barrier function may play an important role
in disease pathogenesis and better understanding of
these mechanisms is required to develop better treat-
ment modalities.12 It seems that there is substantial
need for research to elucidate the so far unknown
mechanisms (Table 1).13
INDUCTION OF IMMUNE TOLERANCE TO
ALLERGENS AS AN ESSENTIAL MECHA-
NISM OF ALLERGEN-SIT
DEVELOPMENT OF DESENSITIZATION OF EF-
FECTOR CELLS
A number of mechanisms is involved in rendering
mast cells and basophils unresponsive to allergens
even if these cells are “sensitized” by specific IgE
bound to their FcεRI receptor. After the first injec-
tions of allergen-SIT, a very early decrease in the sus-
ceptibility of basophils to degranulation and systemic
anaphylaxis can be observed while all of the treated
individuals have high quantities of specific IgE.14 The
rapid desensitization of skin mast cells seems to be
more difficult to achieve.15 The underlying molecular
pathways seem similar to the rapid desensitization of
the efector cells in anaphylactic reactions to drugs.16
Histamine is one of the main mediators released
upon FcεRI triggering of basophils and mast cells,
and it exerts its functions through histamine recep-
tors (HRs).17,18 We recently demonstrated a rapid
upregulation of H2R within the first 6 hours of the
build-up phase of venom-SIT.19 H2R strongly sup-
pressed FcεRI-induced activation and mediator re-
lease of basophils, including histamine and sulfidoleu-
kotrienes, as well as cytokine production in vitro.
These data suggest that immunosilencing of FcεRI-
activated basophils by a selective suppression mecha-
nism mediated by H2R is highly relevant for the very
early desensitization effect of venom-SIT.19 The re-
lease of mediators from mast cells and basophils at
low levels, below the “normal” threshold of systemic
anaphylaxis is probably taking place during allergen-
SIT.20,21 Thus, successful hyposensitization is associ-
ated with the altered magnitude of mediator release
from the effector cells.20
INDUCTION OF PERIPHERAL T CELL TOLER-
ANCE TO ALLERGENS
Generation of allergen-specific Treg cells is central in
the induction of allergen tolerance during allergen-
SIT.22-24 Peripheral tolerance is initiated by IL-10 and
TGF-β, which are increasingly secreted by the
allergen-specific Treg cells during the course of
allergen-SIT.22,23 Both IL-10-secreting (Tr1) and
FOXP3+ (Treg) subsets have been implicated, sug-
gesting that there is an overlap between these sub-
sets of Treg cells in humans.25,26 The supporting evi-
dence for the central role of Treg cells in the induc-
tion of allergen-specific tolerance was provided by the
demonstration of the association of increased num-
bers of FOXP3+CD25+CD3+ cells in the nasal mucosa
after immunotherapy with clinical efficacy and the
suppression of seasonal allergic inflammation.27 CD4+
CD25+ Treg cells from atopic donors are less effective
in the inhibition of proliferation of CD4+CD25− T
cells, which indicates the failing mechanisms of pe-
ripheral allergen tolerance.28 Studies that calculated
the frequency of allergen-specific T cell subsets such
as Th1, Th2 and Tr1 demonstrated a clonal shift to-
wards Tr1 during allergen tolerance.9,29 In addition,
by using human MHC-class II tetramers to investi-
gate allergen-specific T cells during induction of clini-
cal allergen tolerance showed that this led to a switch
in the frequencies of antigen-specific T-cells produc-
ing certain cytokines. There was a marked loss of IL-
4-producing T-cells and an increase in the number of
FOXP3+ and IL-10-producing antigen-specific CD4+ T-
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cells.30 Along these lines, peptide immunotherapy in
asthmatics results in decreased Th2 responses due to
IL-10-dependent peripheral T cell tolerance. Injection
of peptides of selected T cell epitopes from the major
cat allergen Fel d 1 induced suppression of T cell pro-
liferation after stimulation with other “linked” T cell
epitopes from the same molecule.31 Some models,
such as suppression of germinal center reactions and
intestinal lymphoid tissue, show that T cell suppres-
sion can take place both in the secondary lymphoid
organs and in the affected tissues.32
Studies in human high dose allergen exposure
models such as non-allergic bee keepers and cat own-
ers showed that Treg cells specific for the major aller-
gens of venom and cat saliva represent the major T
cell subset in healthy individuals.9,10 They utilize IL-
10, TGF-β, cytotoxic T lymphocyte antigen 4, pro-
grammed death 1 and a number of other suppressive
mechanisms.9,29 The expression of FOXP3 correlates
with the suppressive capacity of Treg cells.33 Consis-
tently, increased FOXP3 expression negatively corre-
lates with IgE, eosinophilia and IFN-γ levels. Remark-
ably, the ratio of FOXP3+ T cells to total CD4+ T cells
is significantly lower in asthmatics or atopic dermati-
tis patients compared to healthy individuals.34
Investigation of Treg cells in allergic individuals
provided further evidence for their role in peripheral
allergen tolerance. It has been shown that mucosal
tolerance induction against dietary antigens coincides
with increased numbers of CD4+CD25+ Treg cells.
Children who developed clinical tolerance to milk
show suppressed peripheral blood mononuclear cell
proliferation to bovine beta-lactoglobulin along with
an increased frequency of circulating CD4+CD25+
Treg cells.35 In allergic children, the numbers of Treg
cells increase during the pollen season, which pro-
vides the mechanism by which other subsets of pol-
len allergen-specific T cells are controlled.36 Notably,
in both healthy and allergic individuals, all three ma-
jor types of allergen-specific subsets of T cells, the
Th1, Th2 and Tr1 cells, are found in different propor-
tions. Thus, the shift in the balance between allergen
specific Th2 and Treg cells is central to either devel-
opment of allergen tolerance or allergic status or
even the recovery from allergic disease.9,29,37
Breaking of peripheral T-cell tolerance to allergens
can lead to the development of allergies, and a recent
study showed some insight into these mechanisms.
Human tonsils show very low levels of allergen-
induced T-cell proliferation, thus representing a very
suitable in vivo model to assess mechanisms of
breaking allergen-specific T-cell tolerance.38 Trigger-
ing of Toll-like receptor 4 or 8 combined with addition
of proinflammatory cytokines IL-1beta or IL-6 breaks
allergen-specific T-cell tolerance in human tonsils and
peripheral blood through a mechanism dependent on
the adaptor molecule myeloid differentiation primary
response gene 88 (MyD88).38 In particular, myeloid
DCs and stimulations that activate these cells medi-
ate the breaking of the tolerant state of allergen-
specific CD4+ T cells, whereas plasmacytoid DCs and
stimulations that activate these cells did not have any
tolerance-breaking effect. Tolerance-breaking condi-
tions induced by different molecular mechanisms
were associated with a mixed cytokine profile with a
tendency toward increased levels of IL-13 and IL-17,
which are Th2 and Th17 cytokines, respectively.
ALLERGEN-SPECIFIC IgE AND IgG RESPONSES
In contrast to the allergen-specific T cells, B cells do
not show tolerance or unresponsiveness to allergens
but are skewed from IgE-producing to IgG4-
producing cells.39 Allergen-SIT induces a transient in-
crease in serum specific IgE followed by a gradual de-
crease usually visible after 3-6 months of treatment.40
Measurements of the IgG subtype levels during SIT
showed specific increases in the range of 10-100 fold
in the concentrations of IgG1 and particularly of
IgG4.41 Specific IgG4 in serum shows a relatively
early and rapid increase and continues to increase
during the whole duration of SIT as it generally re-
flects the total allergen.
The suppressive cytokine IL-10 produced by Treg
cells also affects the immunoglobulin synthesis
through strong suppression of allergen-specific IgE,
while it increases IgG4 production.22,42 Thus, IL-10
regulates specific isotype formation towards a non-
inflammatory phenotype - IgG4.43 IgG4 antibodies are
dynamic molecules that exchange Fab arms by swap-
ping heavy-light chain pairs between IgG4 molecules
with different specificities. This results in the produc-
tion of bispecific antibodies with a substantially de-
creased capacity for cross-linking, because they are
functionally monovalent.44 The IgG4 hinge region has
specialized structural features that result in a lower
affinity for certain Fcγ receptors, and IgG4 does not
fix complement and can inhibit immune-complex for-
mation by other antibody isotypes.45 In addition, IgG4
is a blocking antibody that prevents the activation and
degranulation of effector cells by competing with al-
lergen binding to the IgE on the Fcε receptors of
mast cells and basophils.43,46 The described shift in
immunoglobulin isotype production cannot however,
explain the therapeutic effect of SIT. In general, the
decrease in serum IgE appears much later than clini-
cal tolerance, which occurs relatively early during the
course of SIT and does not correlate with the magni-
tude of clinical improvement after treatment. The pro-
duction of IgE by bone marrow-residing plasma cells
that show a very long life-span might the a plausible
explanation for this discrepancy.47
In a recent study, human inducible IL-10-secreting
B regulatory (Br1) cells and their immunoregulatory
capacity has been investigated in highly purified IL-
10-secreting allergen-specific human B cells.43 Hu-
man Br1 cells produced high levels of IL-10 and po-
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Table　2　Characteristics of a good allergen-SIT vaccine
∙ Should induce long term allergen tolerance (curative)
∙ Should achieve clinical success in short time with few doses
∙ Should target individuals with allergy to identifi ed allergens
∙ Biomarkers should be identifi ed for patient selection and as-
sessment on which population should be targeted, when to
start and stop, and how to follow the patients
∙ To use multiple allergens at the same time should be possi-
ble
∙ Same approach could be useful for the preventive vaccines
tently suppressed antigen-specific CD4+ T-cell prolif-
eration. Interestingly, IgG4 was selectively confined
to human IL-10+ Br1 cells. Healthy beekeeper-derived
B cells specific for the major bee venom allergen
phospholipase A2 showed increased expression of IL-
10. Furthermore as a major contribution to mecha-
nisms of allergen-SIT, the frequency of IL-10+ PLA-
specific B cells was significantly increased in patients
receiving allergen-specific immunotherapy after 3
months demonstrating for the first time a functional
B regulatory cell subset that may play a role in aller-
gen tolerance in humans.43
SUPPRESSION OF EFFECTOR CELLS OF AL-
LERGIC INFLAMMATION
Allergen-SIT efficiently modulates IgE-mediated acti-
vation and histamine release from mast cells and ba-
sophils.48 This process is regulated by Treg cells and
their anti-inflammatory cytokines. Several molecular
mechanisms have been proposed. Through the direct
Treg cell-mast cell contact, Treg cells inhibit FcεRI-
dependent mast cell degranulation.49 IL-10 sup-
presses IL-5 production by human Th2 cells, reduces
proinflammatory cytokine release from mast cells and
downregulates eosinophil function and activity.50
Mast cells are also involved in immune tolerance and
exert suppressive functions in allergic inflammation.
They are capable of downregulating allergic inflam-
mation in UV-induced skin injury and venom-induced
tissue damage models in which IL-10 plays key
role.51,52 Treg cells are potent suppressors in various
models of eosinophilic inflammation including by
schistosome infection-induced as well as asthma-like
lung inflammation in mice.53 Along these lines, de-
creased numbers of eosinophils, eosinophil chemoat-
tractants, and their mediators in the nasal mucosa
have been observed as a long term effect of SIT.54
NOVEL VACCINES FOR ALLERGEN-SIT
The future needs of allergen-SIT include increased ef-
ficacy and patient’s adherence, reduced side effects
and costs and treatment duration (usually 3-5 years).
A good allergen-SIT vaccine should induce long term
allergen tolerance; should achieve clinical success in
short time with few doses; should target individuals
with allergy to identified allergens; biomarkers
should be identified for patient selection and assess-
ment on which population should be targeted, when
to start and stop, and how to follow the patients; the
use of multiple allergens at the same time should be
possible. The same approach could be useful for the
preventive vaccines (Table 2).
Novel approaches to improve the efficacy and
safety of vaccine-based allergen-SIT are outlined in
Table 3. One promising approach includes bypassing
IgE binding to avoid IgE-mediated side effects but
targeting T cells to induce T cell tolerance,55 which is
based on our understanding of the conformation de-
pendence of B cell epitopes and linearity of the amino
acids sequence of T cell epitopes in the three dimen-
tional structure of an allergen. Allergen-fragments, fu-
sions, hybrids and chimeras have been used.55-58 The
prominent example of this approach is peptide immu-
notherapy that utilizes linear T cell epitope pep-
tides.59-61 In addition these modalities enable admini-
stration of higher doses of allergens (or their deriva-
tives) without the risk of anaphylaxis.55,62
The second approach is the use of recombinant al-
lergens or their cocktails, with the aim of partially
mimicking an allergen extract. A study that tried to
reconstruct the native grass pollen allergen extract
using a mixture of five recombinant allergens was ef-
fective in reducing symptoms and the need for symp-
tomatic medication in patients with grass pollen al-
lergy.41 All treated subjects developed high allergen-
specific IgG1 and IgG4 antibody responses. A large
number of clinical trials using recombinant allergens
performed during the last decade showed significant
clinical efficacy compared to the placebo group. Re-
combinant vaccines for grass pollen, birch pollen and
house-dust mite represent the major focus in the fu-
ture development. Vaccines for other allergens may
not prove to be cost effective due to the large number
of minor allergens.63 Another attempt is to physically
couple allergens to stimulators of the innate immune
response. The large diversity of future approaches
relies on infinite possibilities for combinations of mul-
tiple immune stimulators and methods for cou-
pling.64-66
Various routes of vaccine administration are also
investigated. It has been well-documented in the
double-blind, placebo-controlled trials of sublingual
immunotherapy (SLIT) that SLIT is clinical effica-
cious with a treatment benefit that might be slightly
less than that achieved with subcutaneous SIT.67
However the direct comparison of the two different
ways of SIT are not possible at the moment due to
very limited data from the head-to head studies and
diversities in the clinical assessment methodology be-
tween studies. Sustained disease-modifying effects of
SLIT have been established in large-scale random-
ized, double-blind, placebo-controlled trials in both
adults as well as in children.2,68 Although the magni-
tude of the change in most parameters is modest or
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Table　3　Efforts for novel vaccine development for allergen-SIT
Type of the vaccine/approach Description and mechanism
Bypassing IgE binding and targeting T cells
Fusion of major allergens56 and chimeric 
allergens57
Major allergens or their fragments are fused and expressed as a single recombi-
nant protein. T cell reactivity is preserved, IgE binding is attenuated. Preventive 
effect on development of IgE is demonstrated in mice.
Hypoallergenic hybrid molecules80 Derived from Der p 1 and Der p 2, reduced IgE reactivity of hybrid proteins, in-
duce higher T cell proliferation responses.
Fragments of major allergens58 NonIgE binding fragments of major allergen (Bet v 1). IgE binding is attenuated 
and T cell reactivity is preserved.
Peptide immunotherapy59-61 T cell epitope peptides (Fel d 1, Api m 1) that do not bind IgE and induce T cell
tolerance have been used in cat and bee venom allergy.
Unrefolded native or recombinant aller-
gens62
Major recombinant allergens (Api m 1, Bet v 1) are not refolded and lack the na-
tive conformation. IgE binding is abolished, T cell reactivity is protected.
Polymers of major allergens58 Major allergen (Bet v 1) is trimerized. Mast cell, basophil degranulation is attenu-
ated, T cell reactivity is preserved in vitro.
Reconstitution of the natural extract with mixture of multiple recombinant allergens
Mixture of several major recombinant aller-
gens41
Phl p 1, Phl p 2, Phl p 5a, Phl p 5b, Phl p 6 were used as a mixture of fi ve re-
combinant grass pollen allergens.
Allergens coupled to adjuvants that stimulate various aspects of innate immunity
GpG oligonucleotide-conjugated allergens64 Toll-like receptor 9-triggering CpG oligonucleotide is fused to major ragweed al-
lergen Amb a 1.
Allergens coupled to virus-like particles65 Highly repetitive virus capside-like recombinant particles coupled to house dust 
mite major allergen Der p 1.
Carbohydrate-based particles81 Carbohydrate-based particles-bound rPhl p 5b induced a stronger antibody and 
cytokine responses.
Hypoallergenic vaccine based on allergen-
derived peptides fused to hepatitis B PreS82
Recombinant fusion proteins show reduced allergenic activity in basophil activa-
tion and no IgE reactivity.
Monophosphoryl lipid A (MPL) formulated 
with allergoid66
Th1-inducing adjuvant monophosphoryl lipid A (MPL) facilitates short-term SIT 
together with a grass pollen allergoid.
Novel routes of administration
Intralymphatic vaccination73 Allergen-SIT vaccines administered directly into inguinal lymph nodes with the 
aim to deliver high amounts of allergens into secondary lymphatic organs.
Epicutaneous vaccination72 High numbers of antigen presenting cells (LCs), non-vascularized area, safe, 
needle-free, and potentially self-administrable.
Fusion of allergens with immune response modifi ers
Targeting FcγRII74, 75 Fusion of allergens with human Fcγ has been reported to inhibit allergen-induced 
basophil and mast cell degranulation by crosslinking Fcγ and FcεRI receptors.
Modular antigen translocation (MAT) vac-
cines77
The co-expression of major recombinant allergens together with transactivator of 
transcription (Tat) peptide and truncated invariant chain is able to target antigens
to the MHC II molecules in the trans-golgi compartment.
Combination possibility with immune response modifi ers
Pre-treatment with anti-IgE mAb before 
SIT78
To reduce SIT induced side effects. To enable relatively rapid dose increase. To 
use relatively high doses.
no changes have been observed, the immunological
mechanisms of SLIT seem to be similar to subcutane-
ous SIT. In the context of reduced treatment benefits,
and modest changes in immunological markers, the
further improvement of SLIT is to be expected. Multi-
ple mechanisms of immune tolerance are induced by
SLIT, and involve Treg cells, IL-10 production, in-
creased sublingual FOXP3-expressing cells serum in-
hibitory activity for IgE-facilitated allergen binding to
B cells due to elevated allergen-specific IgG4,
IgA.69,70 Allergen-specific FOXP3+ Treg cells have
been found in lingual and palatine tonsils in humans,
and these cells may participate in oral tolerance and
SLIT.71
Other routes of vaccine administration have been
evaluated. The intralymphnode and epicutaneous ap-
plications of vaccine are currently tested. Both routes
showed similar efficacy to subcutaneous injection im-
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munotherapy in grass pollen allergy, but less applica-
tions and lower total doses of allergen were required
using these routes.72,73 T cell responses with strong
cytotoxic activity and IFN-γ production that play a
role in long-term protection against viral infections
and tumors can be induced by intralymphatic vac-
cines.
Another promising strategy is the fusion of aller-
gens to immune modifiers. FcγRIIb is an immune ty-
rosine based inhibitory motif containing receptor.65
The coaggregation of FcεRI and FcγRIIb inhibits
FcεRI signaling. The fusion of the inhibitory receptor
FcγRIIb to allergens to downregulate downstream
allergen-specific immune responses has been investi-
gated. Another fusion protein of allergen and human
Fcγ suppressed allergen-induced degranulation of ba-
sophils and mast cells by crosslinking Fcγ and FcεRI
receptors.74,75 In addition the major cat allergen Fel d
1 was cloned and expressed together with a human
immune deficiency virus protein, TAT-derived mem-
brane translocation domain, and a truncated peptide
of the invariant chain (modular antigen translocation
(MAT)-Fel d 1.76 This MAT-Fel d 1 vaccine is much
more efficiently internalized and potently presented
to T cells by antigen-presenting cells. It induces po-
tent T cell responses at doses that were approxi-
mately 100x lower than those of the native allergens.
In a double-blind, placebo-controlled clinical trial, the
MAT-Fel d 1 vaccine with alum adjuvant was adminis-
tered in three increasing doses (1 μg, 3 μg, 10 μg)
into inguinal, lymph nodes at 4 week intervals. It also
showed a very good safety profile. Cats allergic pa-
tients who were treated with the MAT-Fel d 1 vac-
cines developed clinical tolerance to nasal challenge
of cat dander extract in parallel with increased serum
IgG4.77
Apart from the physical fusion in one agent, the
conventional and novel methods of allergen-SIT may
also be combined with immune-modifying biological
therapies. For example the effectiveness of anti-IgE
combined with allergen-SIT has been demonstrated
in several studies.78 One additional benefit was re-
duced side effects with a significant decrease in the
risk of anaphylaxis caused by rush immunotherapy (a
rapid dose increment approach to reach the mainte-
nance dose as quickly as possible) and improved res-
cue medication scores (so, decreasing the need for a
rescue medication to suppress the symptoms: for ex-
ample anti-histamines for allergic rhinitis) of SIT with
a good safety profile.78,79 These add-on strategies
with biologicals or biosimilars will also expand the
treatment scope of allergen-SIT by including of the
high-risk patients such as food allergy etc. Recent de-
velopments provided hope for better treatments capa-
ble of providing a complete cure for allergic disease.
The findings of the recent studies utilizing the model
of antigen tolerance provided by allergen SIT might
also provide insights into the further therapeutic ap-
proaches in other immune-mediated disease, which
are related to dysregulation of the immune system.
CONCLUSIONS AND FUTURE PERSPEC-
TIVES
Today the major challenges for allergen-SIT include
reducing the number of nonresponders and side ef-
fects, providing a long term recovery or even a com-
plete cure, and reduce the costs as well as the burden
for the patients related to the multiple visits and the
long (3-5 years) duration of the therapy. Thus, there
is a strong rationale for the development of new vac-
cines including potent biological immune response
modifiers as well as new routes of administration.
Prevention strategies for allergic diseases also form a
very exciting horizon. However, the major challenges
include the requirement for very early intervention,
safety problems for a pediatric usage, and missing
early biomarkers of who will develop allergy and to
which particular allergen.
The advances in immunology and bioengineering
are being applied to biologicals to improve their clini-
cal efficacy and feasibility of production by optimizing
their design and clinical efficacy. Novel diagnostic
biomarkers defining the various endotypes will help
to select the best responders and provide them with
an optimized patient-specific treatment. It is generally
thought that the combination of immune response
modifiers with allergen-SIT might provide a way for
efficient immunomodulation of allergic diseases. All
of these approaches could provide a complete and
persistent, life-long cure of allergic disease to a large
number of allergic subjects.
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